- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | CAMBIUM BIO LIMITED: Updated Securities Trading Policy | 2 | ASX | ||
| 30.07. | CAMBIUM BIO LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 24.07. | CAMBIUM BIO LIMITED: Change in substantial holding - BW | - | ASX | ||
| 24.07. | CAMBIUM BIO LIMITED: Cleansing Notice | - | ASX | ||
| 24.07. | CAMBIUM BIO LIMITED: Application for quotation of securities - CMB | - | ASX | ||
| 22.07. | CAMBIUM BIO LIMITED: Proposed issue of securities - CMB | - | ASX | ||
| 22.07. | CAMBIUM BIO LIMITED: Cambium Bio Raises A$1.0 Million via Placement | - | ASX | ||
| CAMBIUM BIO Aktie jetzt für 0€ handeln | |||||
| 24.06. | CAMBIUM BIO LIMITED: Becoming a substantial holder | - | ASX | ||
| 24.06. | CAMBIUM BIO LIMITED: Change in substantial holding - ZYBT | - | ASX | ||
| 16.06. | CAMBIUM BIO LIMITED: Becoming a substantial holder | - | ASX | ||
| 28.04. | CAMBIUM BIO LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 23.04. | CAMBIUM BIO LIMITED: FDA Confirms Single Pivotal Trial Pathway for Elate Ocular | - | ASX | ||
| 24.03. | CAMBIUM BIO LIMITED: Change of Directors Interest Notice - ST | 1 | ASX | ||
| 17.03. | CAMBIUM BIO LIMITED: Cleansing Notice | - | ASX | ||
| 17.03. | CAMBIUM BIO LIMITED: Application for quotation of securities - CMB | - | ASX | ||
| 16.03. | CAMBIUM BIO LIMITED: Results of General Meeting | 2 | ASX | ||
| 20.02. | CAMBIUM BIO LIMITED: Half Year Report and Accounts | - | ASX | ||
| 11.02. | CAMBIUM BIO LIMITED: Proposed issue of securities - CMB | - | ASX | ||
| 11.02. | CAMBIUM BIO LIMITED: Notice of General Meeting/Proxy Form | - | ASX |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,84 | 0,00 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,390 | 0,00 % | If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| QIAGEN | 36,460 | +0,89 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,770 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 361,08 | +0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DYNE THERAPEUTICS | 26,250 | 0,00 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| LATIGO BIOTHERAPEUTICS | 18,250 | 0,00 % | Latigo Biotherapeutics, Inc: Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering | THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. ("Latigo"), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,040 | -0,11 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Executive Chair Transition | BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,290 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BLOSSOMHILL THERAPEUTICS | 15,960 | -0,25 % | BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., ("BlossomHill Therapeutics"), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 22,820 | 0,00 % | Amylyx anticipates Phase III LUCIDITY top-line data in late August or early September with $250.8M cash runway into 2028 | ||
| DISC MEDICINE | 77,44 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 43,490 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,79 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position | Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of... ► Artikel lesen |
Das Unternehmen CAMBIUM BIO LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMBIUM BIO LIMITED finden Sie auf Wallstreet Online.